FENC Q2 2023 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M95.5% margin

Operating Income

-$5M-140.3% margin

Net Income

-$6M-163.7% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+100.9%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$19M

Total Liabilities

$29M

Stockholders' Equity

-$10M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	-$7,931	+40686.8%
Operating Income	-$5M	-$5M	+5.0%
Net Income	-$6M	-$5M	-9.7%